

Table 1. Generalized multifactor dimensionality reduction (GMDR) results of multi-locus interaction with genes related to glaucoma.

GMDR (10 SNPs)	Adjusted for Age, Gender				Adjusted for Age, Gender, Survey Year, Residence Area, BMI			
	Model	TRBA	TEBA	P value	CVC	TRBA	TEBA	P value
<i>ABO_rs2073823</i>	0.547	0.530	8 (0.055)	9/10	0.5458	0.5299	8 (0.055)	9/10
<i>ABO_rs2073823</i> <i>PDE3A_rs12314390</i>	0.569	0.547	9 (0.011)	7/10	0.5677	0.5415	9 (0.011)	6/10
<i>CDKN2B_rs523096</i> <i>ABO_rs2073823</i> <i>CDH13_rs12449180</i>	0.589	0.574	10 (0.001)	9/10	0.5878	0.5736	10 (0.001)	9/10
<i>LDB2_rs3763969</i> <i>CDKN2B_rs523096</i> <i>ABO_rs2073823</i> <i>CDH13_rs12449180</i>	0.607	0.580	10 (0.001)	6/10	0.6055	0.5769	10 (0.001)	5/10
<i>LDB2_rs3763969</i> <i>CDKN2B_rs523096</i> <i>ABO_rs2073823</i> <i>PDE3A_rs12314390</i> <i>CDH13_rs12449180</i>	0.629	0.594	10 (0.001)	10/10	0.6274	0.5927	10 (0.001)	10/10
<i>ZFAT_rs1020236</i> <i>CDKN2B_rs523096</i> <i>ABO_rs2073823</i> <i>CDH13_rs12449180</i> <i>IGF1R_rs1319859</i> <i>SPIRE1_rs3902981</i>	0.653	0.512	5 (0.623)	3/10	0.6500	0.4989	5 (0.623)	3/10
<i>LDB2_rs3763969</i> <i>ZFAT_rs1020236</i> <i>CDKN2B_rs523096</i> <i>ABO_rs2073823</i> <i>CDH13_rs12449180</i> <i>IGF1R_rs1319859</i> <i>SPIRE1_rs3902981</i>	0.684	0.501	4 (0.828)	5/10	0.6803	0.5069	5 (0.623)	3/10
<i>LDB2_rs3763969</i> <i>ZFAT_rs1020236</i> <i>CDKN2B_rs523096</i> <i>ABO_rs2073823</i>	0.715	0.507	7 (0.172)	6/10	0.7105	0.5083	6 (0.377)	5/10

<i>PDE3A</i> _rs12314390									
<i>CDH13</i> _rs12449180									
<i>IGF1R</i> _rs1319859									
<i>SPIRE1</i> _rs3902981									
<i>LDB2</i> _rs3763969									
<i>GLI3</i> _rs1852542									
<i>ZFAT</i> _rs1020236									
<i>CDKN2B</i> _rs523096									
<i>ABO</i> _rs2073823	0.742	0.516	7 (0.172)	8/10	0.7373	0.5120	7 (0.172)	8/10	
<i>TRPC4</i> _rs7335337									
<i>CDH13</i> _rs12449180									
<i>IGF1R</i> _rs1319859									
<i>SPIRE1</i> _rs3902981									
<i>LDB2</i> _rs3763969									
<i>GLI3</i> _rs1852542									
<i>ZFAT</i> _rs1020236									
<i>CDKN2B</i> _rs523096									
<i>ABO</i> _rs2073823	0.765	0.516	7 (0.172)	10/10	0.7603	0.5282	7 (0.172)	10/10	
<i>PDE3A</i> _rs12314390									
<i>TRPC4</i> _rs7335337									
<i>CDH13</i> _rs12449180									
<i>IGF1R</i> _rs1319859									
<i>SPIRE1</i> _rs3902981									

TRBA, trained balanced accuracy; TEBA, test balance accuracy; CVC, cross-validation consistency; sign test, result and P value for the significance of GMDR model by sign test with and without adjusting for covariates designated in the table; BMI, body mass index. *LDB2*, LIM-domain binding protein 2; *CDKN2B*, cyclin-dependent kinase inhibitor 2B; *PDE3A*, phosphodiesterase 3A; *ABO*, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase; *CDH13*, cadherin 13; *GLI3*, GLI family zinc finger 3; *TRPC4*, transient receptor potential cation channel subfamily C member 4; *CDH13*, cadherin 13; *IGF1R*, insulin like growth factor 1 receptor; *SPIRE1*, spire type actin nucleation factor 1.